265 related articles for article (PubMed ID: 23957426)
41. SHP2 is a target of the immunosuppressant tautomycetin.
Liu S; Yu Z; Yu X; Huang SX; Luo Y; Wu L; Shen W; Yang Z; Wang L; Gunawan AM; Chan RJ; Shen B; Zhang ZY
Chem Biol; 2011 Jan; 18(1):101-10. PubMed ID: 21276943
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
43. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
44. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
Guo W; Xu Q
J Pharmacol Sci; 2020 Nov; 144(3):139-146. PubMed ID: 32921395
[TBL] [Abstract][Full Text] [Related]
45. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
LaRochelle JR; Fodor M; Ellegast JM; Liu X; Vemulapalli V; Mohseni M; Stams T; Buhrlage SJ; Stegmaier K; LaMarche MJ; Acker MG; Blacklow SC
Bioorg Med Chem; 2017 Dec; 25(24):6479-6485. PubMed ID: 29089257
[TBL] [Abstract][Full Text] [Related]
46. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
[TBL] [Abstract][Full Text] [Related]
47. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
[TBL] [Abstract][Full Text] [Related]
49. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
50. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
51. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
[TBL] [Abstract][Full Text] [Related]
52. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
53. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Song Y; Zhao M; Zhang H; Yu B
Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
[TBL] [Abstract][Full Text] [Related]
54. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
55. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
56. The role of the protein tyrosine phosphatase SHP2 in ossification.
Zhang Y; Lu W; Zhao Q; Chen J; Wang T; Ji J
Dev Dyn; 2022 May; 251(5):748-758. PubMed ID: 34962674
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
[TBL] [Abstract][Full Text] [Related]
58. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
59. Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors.
Franciosa G; Olsen JV
Oncotarget; 2023 Mar; 14():281-283. PubMed ID: 36999992
[No Abstract] [Full Text] [Related]
60. Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation.
Zhu G; Xie J; Kong W; Xie J; Li Y; Du L; Zheng Q; Sun L; Guan M; Li H; Zhu T; He H; Liu Z; Xia X; Kan C; Tao Y; Shen HC; Li D; Wang S; Yu Y; Yu ZH; Zhang ZY; Liu C; Zhu J
Cell; 2020 Oct; 183(2):490-502.e18. PubMed ID: 33002410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
